- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 683768, 8 pages
Changes of Regulatory T and B Cells in Patients with Papillary Thyroid Carcinoma after 131I Radioablation: A Preliminary Study
1Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China
2Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China
3Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Received 24 July 2013; Accepted 2 September 2013
Academic Editor: Hong Zhang
Copyright © 2013 Lei Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. L. Mazzaferri, “Thyroid cancer,” in Principles and Practice of Endocrinology and Metabolism, K. L. Becker, Ed., pp. 319–331, J. B. Lippincott, Philadelphia, Pa, USA, 1990.
- J. Robbins, M. J. Merino, J. D. Boice Jr. et al., “Thyroid cancer: a lethal endocrine neoplasm,” Annals of Internal Medicine, vol. 115, no. 2, pp. 133–147, 1991.
- F. Gogali, G. Paterakis, G. Z. Rassidakis, et al., “Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, pp. 1474–1482, 2012.
- E. L. Mazzaferri and S. M. Jhiang, “Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer,” The American Journal of Medicine, vol. 97, no. 5, pp. 418–428, 1994.
- J. D. French, Z. J. Weber, D. L. Fretwell, S. Said, J. P. Klopper, and B. R. Haugen, “Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2325–2333, 2010.
- B. Müller-Hübenthal, M. Azemar, D. Lorenzen et al., “Tumour biology: tumour-associated inflammation versus antitumor immunity,” Anticancer Research, vol. 29, no. 11, pp. 4795–4805, 2009.
- A. M. Thornton and E. M. Shevach, “CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production,” Journal of Experimental Medicine, vol. 188, no. 2, pp. 287–296, 1998.
- S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, “Immunologic self-tolerance maintained by activated T cells expressing IL- 2 receptor α-chains (CD25): breakdown of a single mechanism of self- tolerance causes various autoimmune diseases,” Journal of Immunology, vol. 155, no. 3, pp. 1151–1164, 1995.
- W. Liu, A. L. Putnam, Z. Xu-yu et al., “CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells,” Journal of Experimental Medicine, vol. 203, no. 7, pp. 1701–1711, 2006.
- B. Bisikirska, J. Colgan, J. Luban, J. A. Bluestone, and K. C. Herold, “TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs,” Journal of Clinical Investigation, vol. 115, no. 10, pp. 2904–2913, 2005.
- T. J. Curiel, G. Coukos, L. Zou et al., “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004.
- L. R. Javia and S. A. Rosenberg, “CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens,” Journal of Immunotherapy, vol. 26, no. 1, pp. 85–93, 2003.
- U. K. Liyanage, T. T. Moore, H.-G. Joo et al., “Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma,” Journal of Immunology, vol. 169, no. 5, pp. 2756–2761, 2002.
- D. Wolf, A. M. Wolf, H. Rumpold et al., “The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer,” Clinical Cancer Research, vol. 11, no. 23, pp. 8326–8331, 2005.
- C. Jandus, G. Bioley, D. E. Speiser, and P. Romero, “Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood,” Cancer Immunology, Immunotherapy, vol. 57, no. 12, pp. 1795–1805, 2008.
- A. M. Miller, K. Lundberg, V. Özenci et al., “CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients,” Journal of Immunology, vol. 177, no. 10, pp. 7398–7405, 2006.
- A. Bamias, V. Koutsoukou, E. Terpos et al., “Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy,” Gynecologic Oncology, vol. 108, no. 2, pp. 421–427, 2008.
- T. Schneider, S. Kimpfler, A. Warth et al., “Foxp3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma,” Journal of Thoracic Oncology, vol. 6, no. 3, pp. 432–438, 2011.
- S. Hinz, L. Pagerols-Raluy, H.-H. Oberg et al., “Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer,” Cancer Research, vol. 67, no. 17, pp. 8344–8350, 2007.
- D. J. Dilillo, T. Matsushita, and T. F. Tedder, “B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer,” Annals of the New York Academy of Sciences, vol. 1183, pp. 38–57, 2010.
- P. A. Blair, L. Y. Noreña, F. Flores-Borja et al., “CD19+ B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients,” Immunity, vol. 32, no. 1, pp. 129–140, 2010.
- D. Maseda, S. H. Smith, D. J. DiLillo et al., “Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo,” Journal of Immunology, vol. 188, no. 3, pp. 1036–1048, 2012.
- F. Hua, L. Ji, Y. Zhan, et al., “Pulsed high-dose dexamethasone improves interleukin 10 secretion by CD5+ B cells in patients with primary immune thrombocytopenia,” Journal of Clinical Immunology, vol. 32, no. 6, pp. 1233–1242, 2012.
- Q. Y. Luo, “Clinical value and indications of 131I treatment after surgery for differentiated thyroid cancer,” Journal of Nuclear Medicine & Radiation Therapy, vol. 3, article e104, 2012.
- M. Schlumberger, B. Catargi, I. Borget et al., “Strategies of radioiodine ablation in patients with low-risk thyroid cancer,” The New England Journal of Medicine, vol. 366, no. 18, pp. 1663–1673, 2012.
- R. J. Robbins and M. J. Schlumberger, “The evolving role of 131I for the treatment of differentiated thyroid carcinoma,” Journal of Nuclear Medicine, vol. 46, no. 1, p. 28, 2005.
- L. L. Cunha, A. J. Tincani, L. V. M. D. Assumpção, F. A. Soares, J. Vassallo, and L. S. Ward, “Interleukin-10 but not interleukin-18 may be associated with the immune response against well differentiated thyroid cancer,” Clinics, vol. 66, no. 7, pp. 1203–1208, 2011.
- L. L. Cunha, E. C. Morari, S. Nonogaki, F. A. Soares, J. Vassallo, and L. S. Ward, “Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas,” Clinics, vol. 67, no. 5, pp. 483–488, 2012.
- A. Sellitto, G. Galizia, U. De Fanis et al., “Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery,” Journal of Clinical Immunology, vol. 31, no. 6, pp. 1095–1104, 2011.
- T. W. Lebien and T. F. Tedder, “B lymphocytes: how they develop and function,” Blood, vol. 112, no. 5, pp. 1570–1580, 2008.
- K. Yanaba, J.-D. Bouaziz, T. Matsushita, C. M. Magro, E. W. St.Clair, and T. F. Tedder, “B-lymphocyte contributions to human autoimmune disease,” Immunological Reviews, vol. 223, no. 1, pp. 284–299, 2008.
- J.-D. Bouaziz, K. Yanaba, G. M. Venturi et al., “Therapeutic B cell depletion impairs adaptive and autoreactive CD4 + T cell activation in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20878–20883, 2007.
- F. E. Lund, “Cytokine-producing B lymphocytes: key regulators of immunity,” Current Opinion in Immunology, vol. 20, no. 3, pp. 332–338, 2008.
- Q. Y. Luo, L. B. Chen, Y. L. Yu, H. K. Lu, and R. S. Zhu, “Changs in lymphocytes subsets in differentiated thyroid cancer treated with 131I,” Chinese Journal of Endocrinology and Metabolism, vol. 22, pp. 52–54, 2006.
- F. Martin and A. C. Chan, “B cell immunobiology in disease: evolving concepts from the clinic,” Annual Review of Immunology, vol. 24, pp. 467–496, 2006.
- S. Lindner, K. Dahlke, K. Sontheimer, et al., “Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells,” Cancer Research, vol. 15, no. 73, pp. 2468–2479, 2013.
- C. Asseman, S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie, “An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation,” Journal of Experimental Medicine, vol. 190, no. 7, pp. 995–1003, 1999.
- F. Cottrez, S. D. Hurst, R. L. Coffman, and H. Groux, “T regulatory cells 1 inhibit a Th2-specific response in vivo,” Journal of Immunology, vol. 165, no. 9, pp. 4848–4853, 2000.
- A. O'Garra, G. Stapleton, V. Dhar et al., “Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10,” International Immunology, vol. 2, no. 9, pp. 821–832, 1990.
- M. Murai, O. Turovskaya, G. Kim et al., “Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis,” Nature Immunology, vol. 10, no. 11, pp. 1178–1184, 2009.